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Pharmacology, University College London, Gower Street,
London WC1E 6BT, UKAbstract—Voltage-gated sodium channel blockers are not
traditionally recommended for osteoarthritis (OA) pain ther-
apy, but given the large peripheral drive that follows OA
development there is a rationale for their use. Using a rat
model of monosodium iodoacetate (MIA)-induced OA we
used in vivo electrophysiology to assess the eﬀects of the
Nav1.7- and Nav1.8-selective antagonists, ProTxII and A-
803467 respectively, on the evoked activity of spinal dorsal
horn neurons in response to electrical, mechanical and ther-
mal stimuli applied to the peripheral receptive ﬁeld. These
studies allow examination of the roles of these channels in
suprathreshold stimuli, not amenable to behavioral thresh-
old measures. Spinal administration of ProTxII signiﬁcantly
reduced neuronal responses evoked by mechanical punc-
tate (von Frey (vF) 8–60 g) and noxious thermal (45 and
48 C) stimuli in MIA rats only. A-803467 signiﬁcantly inhib-
ited neuronal responses evoked by vF 8–60 g and 48 C heat
after spinal administration; signiﬁcantly inhibited responses
evoked by brush, vFs 26–60 g and 40–48 C stimuli after sys-
temic administration; signiﬁcantly inhibited the electrically
evoked Ad-, C-ﬁber, post-discharge, Input and wind-up
responses and the brush, vFs 8–60 g and 45–48 C evoked
neuronal responses after intra plantar injection in the MIA
group. In comparison A-803467 eﬀects in the sham group
were minimal and included a reduction of the neuronal
response evoked by vF 60 g and 45 C heat stimulation after
spinal administration, no eﬀect after systemic administra-
tion and an inhibition of the evoked response to 45 C heat
after intra plantar injection only. The observed selective
inhibitory eﬀect of ProTxII and A-803467 for the MIA-treated
group suggests an increased role of Nav1.7 and 1.8
within nociceptive pathways in the arthritic condition,
located at peripheral and central sites. These ﬁndings
demonstrate the importance of, and add to, the mechanistic
understanding of these channels in osteoarthritic pain.http://dx.doi.org/10.1016/j.neuroscience.2015.03.042
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INTRODUCTION
Osteoarthritis (OA) constitutes one of the largest cost
burdens to healthcare in the western world with pain
being the dominant symptom and reason for clinical
presentation (Hiligsmann et al., 2013; Neogi, 2013).
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are
ﬁrst-line treatments, often in combination with paraceta-
mol or opioids, but analgesic eﬃcacy is largely modest
at best at tolerable doses, or is hampered by signiﬁcant
adverse eﬀects with dose escalation (Harvey and
Hunter, 2010; Zhang et al., 2010a). For these reasons,
many patients resort to total joint replacement to relieve
their pain, yet chronic pain remains for a signiﬁcant pro-
portion (about 20–40%) of patients (Kirwan et al., 1994;
Creamer et al., 1996; Ethgen et al., 2004). This highlights
the complexity of OA pain and the signiﬁcant unmet clini-
cal need.
OA is characterized by inﬂammation (episodic and
chronic) and swelling of joints and also signiﬁcant pain
in the area surrounding the joint and often in areas
distant to the aﬀected joint (referred pain), thus
suggesting that both peripheral and central nociceptive
mechanisms are at play (Farrell et al., 2000; Malfait and
Schnitzer, 2013; Zhang et al., 2013). The transmission
of pain from the peripheral site of injury, beyond the
peripheral transducers, requires activation of voltage-
gated sodium channels (VGSCs) located on peripheral
nociceptors. Abundant data exist showing that maladap-
tive changes in VGSCs are critical for mediating variety
of chronic pain conditions in both animals and humans
(Eijkelkamp et al., 2012; Dib-Hajj et al., 2013) thus modu-
lating their activity is a rational strategy for chronic pain
therapy.
Sodium channel blockers for the treatment of OA pain
are not currently recommended, yet they may have a key
role in controlling OA pain since there is strong evidence
for abnormal ﬁring in peripheral and central neurons in the
arthritic condition, which must involve alterations in
VGSCs (Schuelert and McDougall, 2006, 2008, 2009;/licenses/by/4.0/).
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2010; Kelly et al., 2012, 2015; Bullock et al., 2014) and a
genetic mutation in the encoding gene for the 1.7 sodium
channel sub-type has been correlated with increased pain
sensitivity in OA patients (Reimann et al., 2010) but see
(Valdes et al., 2011). Furthermore, analgesic eﬃcacy of
the lidocaine patch and intravenous and intra-articular
injection of non-selective VGSC blockers has been
observed in osteoarthritic patients (Creamer et al., 1996;
Burch et al., 2004; Gammaitoni et al., 2004; Kivitz et al.,
2008; Dworkin et al., 2011; Duarte et al., 2014).
There is a rationale for sodium channel blockers for
OA pain therapy, based on heightened peripheral drive,
which could be present in both early inﬂammatory and
later non-inﬂammatory stages. In addition there may be
neuropathic components to the pain in sub-groups of
patients (Duarte et al., 2014; Thakur et al., 2014). Our
aim was to further characterize the role of Nav1.7 and
1.8 channels in a rat model of monosodium iodoacetate
(MIA) (2 mg)-induced OA of the knee joint; a well-estab-
lished model for the mechanistic study of osteoarthritic
pain that has also been pharmacologically validated with
respect to established analgesics including NSAIDs
(Vonsy et al., 2008; Zhang et al., 2013). This dose of
MIA (2 mg) has been shown to produce an up-regulation
of the neuronal damage marker, cAMP-dependent tran-
scription factor (ATF-3), in peripheral nerves that inner-
vate the knee joint, a reduction in intra-epidermal nerve
ﬁber density and alterations in spinal cord neuroimmune
cells (Ivanavicius et al., 2007; Im et al., 2010; Thakur
et al., 2012, 2014) features that are consistent with neu-
ropathy. Therefore this model would be useful for assess-
ing the analgesic potential of drugs for OA patients with
neuropathic traits (Hochman et al., 2011; Duarte et al.,
2014). Using in vivo electrophysiology, we have investi-
gated, for the ﬁrst time, the eﬀects of ProTxII, a tarantula
toxin that potently inhibits Nav1.7 channels with about ﬁf-
teen to a hundred fold selectivity over other VGSCs
(Middleton et al., 2002; Schmalhofer et al., 2008; Xiao
et al., 2010), and A-803467, a selective Nav1.8 VGSC
blocker (Jarvis et al., 2007), on the evoked activity of wide
dynamic range (WDR) dorsal horn neurons in response to
stimulation of the peripheral receptive ﬁeld in this model of
OA. The eﬀects of ProTxII were examined after topical
spinal application only because it was previously shown
that ProTx-II only inhibited C-ﬁber action potential prop-
agation in desheathed but not in intact nerve prepara-
tions, suggesting that the toxin could not penetrate the
blood nerve barrier (Schmalhofer et al., 2008). For this
reason we did not extend our ProTxII study to intraplantar
and systemic routes as we did not expect that the toxin
would be able to reach the channel. The eﬀects of the
selective Nav1.8 channel blocker A-803467 given via
three diﬀerent routes of administration (topical spinal, sys-
temic and intraplantar injection) were assessed in order to
shed light on the sites of action of the drug. In vivo elec-
trophysiology allows for spinal nociceptive processing
and central sensitization to be studied experimentally
and provides information on suprathreshold responses,
which are likely to equate to high levels of pain transmis-
sion as reported by patients, therefore adding tobehavioral data where the analgesic eﬀect of drugs on
threshold responses are generally measured.
EXPERIMENTAL PROCEDURES
Sprague–Dawley rats (Central Biological Services,
University College London, UK) weighing 130–140 g at
time of injection and 240–270 g at time of in vivo
electrophysiology were employed for this study. All
experimental procedures were approved by the UK
Home Oﬃce and followed the guidelines under the
International Association for the Study of Pain
(Zimmermann, 1983).
Induction of OA
On day 0 isoﬂurane anesthetized Sprague–Dawley rats
received an intra-articular injection of 2–mg MIA in 25 ll
of 0.9% saline through the infrapatellar ligament of the
knee. Sham animals were injected with sterile 0.9%
saline only. Following injection animals were allowed to
recover and then re-housed in cages under a 12-h
alternating light/dark cycle with ad libitum access to food
and water.
Assessment of pain related behaviorDevelopment of mechanical and cooling
hypersensitivity. Behavioral responses to stimulation of
the ipsilateral hind paw were recorded once the animals
had acclimatized to the testing area (Perspex cages with
a wire mesh ﬂoor) for at least 30 min. Tactile
hypersensitivity was tested by touching the plantar
surface of the hindpaw with von Frey (vF) ﬁlaments
(Touch-test TM, North Coast Medical Inc., San Jose, CA,
USA) using the ‘‘up-down method’’ (Chaplan et al.,
1994), starting with 2.0 g then ranging from 0.4 g to 15 g.
Positive withdrawals were counted as biting, licking and
withdrawal during or immediately following the stimulus.
The strength of the vF ﬁlament was increased or
decreased following a negative or positive response
respectively. This up-down procedure was applied 4 times
following the ﬁrst change in response. Data are presented
as 50% paw withdrawal threshold (PWT) for each
group ± standard error of the mean (SEM). Sensitivity to
cooling stimulation was assessed as the number of with-
drawals out of a trial of ﬁve applications of a drop of ace-
tone to the plantar surface of the ipsilateral hind paw.
Paw withdrawal frequency (PWF) was quantiﬁed and pre-
sented as a percentage of themaximal response i.e. (num-
ber of foot withdrawals/ﬁve trials)  100.
Hind-limb weight bearing. Changes in hind paw weight
bearing was measured using an incapacitance tester
(Linton instruments, Norfolk, UK). Animals were placed
in a perspex chamber designed so that the animal is
upstanding and the hindpaws rest on a separate small
electronic balance so that the weight distributed on the
right and left hind paw could be measured. Once the
animal was settled three consecutive readings (each
measured over 3 s) were recorded. The average of a
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for each rat and used for subsequent analyses. The
weight bearing of the ipsilateral hindpaw to knee
injection is presented as a percentage of the total
weight bearing of both hind limbs.
In vivo electrophysiology
Two weeks after MIA injection in vivo electrophysiological
studies were performed (post MIA injection days 15 and
16) as previously described (Rahman et al., 2009).
Brieﬂy, animals were anesthetized and maintained for
the duration of the experiment with isoﬂurane (1.5–
1.7%) delivered in a gaseous mix of N2O (66%) and O2
(33%). A laminectomy was performed to expose the L4–
5 segments of the spinal cord. Extracellular recordings
were made from ipsilateral deep dorsal horn neurons
(lamina V–VI) using parylene-coated tungsten electrodes
(A-M Systems, Sequim, WA, USA). All the neurons
recorded in this study were WDR since they all responded
to both light touch and noxious inputs (pinch and noxious
heat); further all neurons responded to natural stimuli in a
graded manner with coding of increasing intensity.
The evoked response to a train of 16 transcutaneous
electrical stimuli (2 ms wide pulses, 0.5 Hz) applied at
three times the threshold current for C-ﬁber activation of
the dorsal horn cell. The train of electrical stimuli was
delivered via stimulating needles inserted into the
peripheral receptive ﬁled, following which a post-stimulus
histogram was constructed. Responses evoked by
Ab- (0–20 ms), Ad- (20–90 ms) and C-ﬁbers (90–350 ms)
were separated and quantiﬁed on the basis of latency.
Responses occurring after the C-ﬁber latency band were
taken to be the post-discharge of the cell (350–800 ms).
Two other measures of electrically evoked neuronal
activity were made. The ‘‘Input’’ which is calculated as
the number of action potentials evoked by the ﬁrst
stimulus (due to C-ﬁber activity) in the train of electrical
stimuli response multiplied by 16; thus ‘‘Input’’ is a
measure of the non-potentiated response i.e. the
baseline C-ﬁber-evoked response which is likely a
measure of aﬀerent input and the resultant spinal
neuronal response prior to central neuronal
hyperexcitability evoked by subsequent stimuli. We also
measured ‘‘Wind-up’’ which is calculated as the total
number of action potentials evoked by C-ﬁber activity
subtracting the Input. This potentiated response seen as
increased neuronal activity in response to constant
repetitive C-ﬁber stimulation is a measure of central
sensitization. The center of the peripheral receptive ﬁeld
was also stimulated using mechanical punctate and
thermal stimuli (vF ﬁlaments, 2, 8, 26 and 60 g and heat,
applied with a constant water jet, 40, 45 and 48 C)
Application of each von Frey hair was separated by a
minimum interval period of 5–10 s, and longer for very
responsive neurons at the higher intensity range.
Application of each subsequent heat stimulus was
separated by a minimum period of 1 min. All natural
stimuli were applied for a period of 10 s per stimulus. The
mechanical and thermal natural evoked neuronal
response was recorded as the number of action
potentials evoked during the 10-s stimulation applicationperiod. Data were captured and analyzed by a CED 1401
interface coupled to a Pentium computer with Spike 2
software (Cambridge Electronic Design; PSTH and rate
functions).
Pharmacological assessment was carried out on one
neuron only per animal. The testing procedure was
carried out every 20 min and consisted of a train of
electrical stimuli followed by natural stimuli as described
above. It should be noted that the train of electrical
stimuli may be sensitizing and could enhance
subsequent test responses. Thus, expression of some
of the eﬀects reported might depend upon this prior
sensitization. Following three consecutive stable control
trials (<10% variation for the C-ﬁber evoked response,
and <20% variation for all other parameters) neuronal
responses were averaged to give the pre-drug control
values. Then either ProTxII, diluted in saline 0.9% was
given via topical spinal application (0.005 and 0.05 lg/
50 ll) or A-803467 diluted with 95% polyethylene glycol
and 5% dimethylsulfoxide solution, via topical spinal
application (10 and 50 lg/50 ll) or systemically via
subcutaneous injection into the scruﬀ of the neck (3 and
30 mg/kg) or via intraplantar injection into the ipsilateral
hindpaw (10 and 50 lg/50 ll). The selection of A-
803467 and ProTxII doses were based on earlier
studies (Jarvis et al., 2007; McGaraughty et al., 2008;
Schmalhofer et al., 2008). The eﬀect of each dose was
followed for an hour, with tests (train of electrical stimuli
followed by mechanical and thermal stimulation of the
peripheral receptive ﬁeld, in that order) carried out at 10,
30 and 50 min before the next dose was applied cumula-
tively. A trend for the greatest eﬀect was seen at either the
10- or 30-min time point (for both drugs and routes). Using
this protocol the evoked responses are stable over sev-
eral hours. The lack of eﬀect of the low dose of either drug
evidences this stability.
Statistics
All statistical tests were performed on raw data using
GraphPad Prism 5 (GraphPad software, La Jolla, CA,
USA) and for all data a 95% conﬁdence interval was
used as a measure of statistical signiﬁcance. For in vivo
electrophysiology measures, statistical signiﬁcance was
tested using non-parametric Mann–Whitney test to
compare two groups of data and a one-way or two-way
repeated-measures analysis of variance (RM ANOVA),
followed by a Bonferroni corrected paired t-test when
simultaneously comparing more than two groups of data.
Drug eﬀects were measured as the maximum change
from the averaged pre-drug control values for each dose
(seen at 10-, 30- or 50-min time point) on each response
per neuron (the electrophysiological unit is the number of
action potentials evoked by a given stimulus). The
overall eﬀect of the drug was then expressed and
presented as the mean maximal evoked neuronal
response for each dose ± SEM. A one-way RM ANOVA
was used to evaluate drug eﬀects on the neuronal
responses evoked by electrical and dynamic brush
stimulation and a 2-way RM ANOVA was used to
evaluate drug eﬀects on the neuronal responses evoked
by mechanical or heat stimulation in MIA or control rats.
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MIA-induced behavioral hypersensitivity
A signiﬁcant decrease in PWT to mechanical stimulation,
a signiﬁcant increase in PWF to cooling stimulation of
the ipsilateral hind paw and a signiﬁcant decrease in
hind limb weight bearing of the side ipsilateral to
MIA injection, compared with sham rats, conﬁrmed OA
pain development; PWT: MIA 2.9 ± 0.2 g vs Sham
11.5 ± 1 g, PWF: MIA 3.6 ± 0.4 lifts vs Sham
1.1 ± 0.3 lifts and weight bearing: MIA 33.7 ± 1.3% vs
Sham 48.5 ± 2% at day 14 post model induction, MIA
(n= 28) vs Sham (n= 27), p< 0.05, Mann–Whitney
test (data not shown). These ﬁndings are in line with a
previous study (Rahman and Dickenson, 2014).In vivo electrophysiology – evoked responses of
dorsal horn neurons
The eﬀect of ProTxII or A-803467, delivered via spinal,
systemic or intraplantar route, was assessed upon the
evoked responses of deep dorsal horn (Lamina V–VI)
neurons to electrical and natural mechanical and
thermal stimulation of their peripheral receptive ﬁeld.
Comparison of the average baseline pre-drug responses
for MIA and shams per drug and per route of
administration (spinal or systemic) revealed a
signiﬁcantly greater C-ﬁber and vF 60 g evoked
response in the MIA group vs sham in the ProTxII study
(p< 0.05 Mann–Whitney test, Fig. 1 a vs b); a
signiﬁcantly greater response evoked by 40 C
stimulation in the MIA vs sham group in the A-803467
‘‘systemic’’ study (p< 0.05 Mann Whitney test, Fig. 3 a
vs b) and a signiﬁcantly greater response evoked by vF
8 g in the MIA vs sham group in the A-803467
‘‘intraplantar’’ study (p< 0.05 Mann–Whitney test,
Fig. 4 a vs b). All other baseline neuronal responses
were not signiﬁcantly diﬀerent between MIA and sham
groups. However, this study was not powered to
compare baseline neuronal responses between MIA and
sham groups, therefore any diﬀerences in the average
baseline neuronal responses were not further analyzed
or emphasized. Although in an earlier study, where we
characterized a large number of cells, we observed, on
average, greater ﬁring of neurons in response to
mechanical and thermal stimulation in the MIA group,
but not to electrical or brush stimuli (Rahman et al., 2009).
MIA-dependent antinociceptive eﬀect of ProTxII on the
mechanical and thermal evoked responses of spinal
dorsal horn neurons. Topical spinal application of
ProTxII did not produce any signiﬁcant eﬀects on any of
the electrical stimuli, indicating a lack of eﬀect on
excitability, or brush-evoked neuronal responses in
either group (Fig. 1a–d). In contrast, a clear MIA-
dependent antinociceptive eﬀect of ProTxII was
observed on many of the natural mechanical punctate
and thermal evoked responses. The low-thresholdmechanical response evoked by vF 8 g applied to the
peripheral receptive ﬁeld was signiﬁcantly inhibited by
the top dose of ProTxII (0.05 lg) and a dose-dependent
inhibition with 0.005 and 0.05 lg ProTxII was seen of the
evoked neuronal response to noxious mechanical (vF 26
and 60 g) stimulation of the peripheral receptive ﬁeld in
the MIA group only (Fig. 1f). Similarly, ProTxII, was able
to reduce the neuronal response to noxious heat (45 and
48 C) stimulation in the MIA group only, with both doses
producing an equivalent degree of signiﬁcant inhibition
(Fig. 1h). It has previously been shown that 0.01 mg/kg
i.t. produces a plasma concentration of 3 nM
(signiﬁcantly lower than the IC50 for other Nav channels)
(Schmalhofer et al., 2008), the doses we have used here
equate to approximately 0.02–0.2 lg/kg i.t. (based on a
250 g rat) and are considerably lower. Therefore, since
the dose used by Schmalhofer et al. (2008) was shown
to produce Nav1.7-speciﬁc inhibition, it is reasonable to
assume that the inhibitory eﬀects of ProTx-II on the
evoked dorsal horn neurons seen in the present study
reﬂect a blockade of Nav1.7 channel activity and not other
Nav channels or other oﬀ-target eﬀects.Spinal administration of A-803467 produced a marked
and signiﬁcant inhibition of the evoked responses of
dorsal horn neurons to mechanical and thermal stim-
ulation in the MIA group. Spinal administration of A-
803467 reduced some of the electrical evoked neuronal
responses in both MIA and sham groups, but these
eﬀects did not reach signiﬁcance (Fig. 2a, b). In
complete contrast, A-803467 produced a clear MIA
group-dependent inhibition of many of the mechanical-
and thermal evoked neuronal responses; in particular
the mechanical evoked responses in the MIA group
were highly sensitive to the inhibitory eﬀects of A-
803467 (Fig. 2d, f).
In the MIA group, A-803467 inhibited the evoked
neuronal response to brush stimulation, which was
signiﬁcant with the top dose of the drug (50 lg) (Fig.
2d). A-803467, at both doses, signiﬁcantly and markedly
inhibited the neuronal responses evoked by vFs 8–26 g,
(Fig. 2f). The thermal evoked neuronal responses in
MIA rats were also inhibited by spinal administration of
A-803467, with a signiﬁcant inhibition of the response
evoked by 48 C stimulation seen with the top dose
(50 lg) only (Fig. 2h).
The eﬀects of spinal administration of A-803467 on
the evoked neuronal responses in the sham control rats
were minimal. A-803467 produced a non-signiﬁcant
trend toward inhibition of the electrical C-ﬁber-evoked
neuronal response and the PD measure of neuronal
excitability. The mechanical punctate and thermal
evoked neuronal responses in the sham animals were
largely resistant to the eﬀects of the drug, with the top
dose of A-803467 producing a signiﬁcant reduction of
the evoked neuronal response to vF 60 g and 48 C
stimulation only (Fig. 2e, g).
The selective eﬀects of A-803467 for Nav1.8 channels
in reducing the behavioral and neuronal measures of
nociception have been established in other models of
chronic pain (Jarvis et al., 2007; McGaraughty et al.,
Fig. 1. Neuronal responses evoked by vF 8–60 g and 45 and 48 C heat stimulation and were signiﬁcantly reduced by ProTxII in the MIA group
only. Comparison of the eﬀects of spinal administration of ProTxII (0.005 and 0.05 lg/50 ll) on the evoked neuronal responses to electrical (a,b),
dynamic brush (c,d), mechanical punctate (e, f) and thermal stimulation (g,h) of the peripheral receptive ﬁeld in sham (n= 8, left panel) and MIA
(n= 7, right panel) rats. §Denotes signiﬁcance at 0.005 lg, and ⁄denotes signiﬁcance at 0.05 lg compared with pre-drug baseline control data,
p< 0.05, two-way RM ANOVA with Bonferroni test for multiple paired comparisons. Values are mean ± SEM.
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Fig. 2. Neuronal responses evoked by brush, vF 8–60 g and 48 C heat were signiﬁcantly inhibited after spinal administration of A-803467 in the
MIA group. Comparison of the eﬀects of topical spinal administration of A-803467 (10 and 50 lg/50 ll) on the evoked neuronal responses to
electrical (a,b), dynamic brush (c,d), mechanical punctate (e, f) and thermal stimulation (g,h) of the peripheral receptive ﬁeld in sham (n= 6, left
panel) and MIA (n= 7, right panel) rats. Asterisks and bars denote statistically signiﬁcant main eﬀect (one-way RM ANOVA). §Denotes signiﬁcance
at 10 lg, ⁄denotes signiﬁcance at 50 lg compared with baseline control data, p< 0.05, two-way RM ANOVA with Bonferroni test for multiple paired
comparisons. Values are mean ± SEM.
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sent study equate to 28–140 nmol/50 ll which are con-
siderably lower than those used by McGaraughty et al.,
2008 (McGaraughty et al., 2008.) Therefore it is likely that
the inhibitory eﬀects of spinal administration of A-803467
seen in the present study reﬂect a selective blockade of
Nav1.8 channels and not other Nav channels.
MIA-dependent antinociceptive eﬀect of mechanical
and thermal evoked responses of dorsal horn neurons
following systemic administration of A-803467. The
systemic doses of A-803467 used in the present study
are in line with those used in earlier studies in diﬀerent
models of chronic pain (Jarvis et al., 2007;
McGaraughty et al., 2008). The electrical evoked neu-
ronal responses were not signiﬁcantly aﬀected by sys-
temic administration of A-803467 (3 and 30 mg/kg) to
either group (Fig. 3a, b), in line with the lack of eﬀect of
the drug on these neuronal measures after spinal applica-
tion. A signiﬁcant inhibition of the mechanical brush and
vFs 26–60 g and thermal, 40–48 C, evoked neuronal
responses was seen in the MIA-treated group only, sug-
gesting an MIA-dependent anti-hyperalgesic action of
30 mg/kg A-803467 via sub cutaneous administration
(Fig. 3f, h). In comparison these doses of A-803467 had
no signiﬁcant eﬀect on any neuronal measure in the sham
group.
Intraplantar administration of A-803467 inhibited the
electrical, mechanical and thermal evoked responses of
dorsal horn neurons in the MIA group. Intraplantar
administration of A-803467 (10 lg and 50 lg/50 ll)
produced a marked and signiﬁcant inhibition of nearly all
the evoked neuronal responses in the MIA group. Both
doses of the drug inhibited the electrically evoked Ad
and C-ﬁber responses as well as the neuronal
excitability measures of post-discharge, Input and Wind-
up, indicative of this peripheral route allowing
attenuation of nerve excitability or propagation. The
mean response evoked by dynamic brush, vFs 8–60 g
and 45–48 C heat was signiﬁcantly inhibited by both
doses of A-803467 (Fig. 4b, d, f, h). In contrast, in the
sham control group, the top dose of A-803467 was
eﬀective in reducing the Input and neuronal response
evoked by 45 C heat stimulation only (Fig. 4a, g).
The doses of A-803467 given by intraplantar injection
in the present study equate to 28 and 140 nmol/50 ll and
are lower than the dose used by others, where a
signiﬁcant and selective inhibitory eﬀect of A-803467 on
the evoked responses of WDR neurons was seen
following injection of 300 nmol/50 ll into the hind paw
receptive ﬁeld (McGaraughty et al., 2008). Therefore the
inhibitory eﬀects of A-803467 following intraplantar injec-
tion seen in the present study likely reﬂect a selective
blockade of Nav1.8 channels and not other Nav channels.
DISCUSSION
OA is a progressive and degenerative disease of the
whole joint and typically includes a destruction and
degradation of the articular cartilage, subchondral bone,synovial lining and connective tissues (Vincent and
Watt, 2014). In this study we have used the MIA model
of OA. This is a chemically induced, rapidly progressive
model that is well described in the rat especially in terms
of its disease pathology (Guzman et al., 2003) and mirrors
many aspects of the human condition, and has so far
proved useful for the understanding of osteoarthritic pain
mechanisms (Zhang et al., 2013). In addition this dose of
MIA has been shown to produce OA associated with
markers of neuropathy (Ivanavicius et al., 2007; Im
et al., 2010; Thakur et al., 2012, 2014) and therefore
may be indicative of those patients with advanced disease
that display an additional neuropathic pain phenotype
(Hochman et al., 2011; Duarte et al., 2014). Knee joint
pathology was not assessed here, however we have pre-
viously demonstrated cartilage loss following injection of
2 mg of MIA, which is characteristic of human OA,
(Thakur et al., 2012) as have others (Fernihough et al.,
2004; Pomonis et al., 2005; Im et al., 2010), also MIA
injection produced hypersensitivity to mechanical and
cooling stimulation of the ipsilateral hind paw and a
decrease in hind limb weight bearing of the injected side
conﬁrming OA pain development (Vincent et al., 2012;
Malfait et al., 2013).
The behavioral hypersensitivity to stimulation of the
ipsilateral hind paw, i.e. the referred receptive ﬁeld area,
reﬂects secondary hyperalgesia, which is indicative of
central sensitization. Pain symptoms elicited by various
activities such as bending or walking in patients with
knee OA are largely associated with the area
surrounding the aﬀected joint, but referred pain and
tenderness also occurs implicating mechanisms of
central sensitisation contributing to their pain (Farrell
et al., 2000; Bajaj et al., 2001; Gwilym et al., 2009;
Graven-Nielsen and Arendt-Nielsen, 2010; Aranda-
Villalobos et al., 2013), and a direct link between the level
of sensitization in referred areas and clinical pain intensity
experienced by OA patients has been shown (Arendt-
Nielsen et al., 2010). Therefore the data presented here
provide for an electrophysiological and behavioral corre-
late for the spread of sensitization seen in OA patients
and allows for the study of spinal nociceptive processing
and central sensitization mechanisms.
Referred pain is dependent not only on central
hyperexcitability but also on input from the periphery
(Laursen et al., 1997; Graven-Nielsen and Arendt-
Nielsen, 2010; Baron et al., 2013), therefore there is a
logical basis for targeting this, and central neuronal
excitability, by blocking sodium channel function, thus
reducing action potential generation and transmission.
In this study, we assessed the eﬀects of two diﬀerent
sodium channel blockers, ProTxII and A-803467, which
block Nav1.7 and Nav1.8 channels respectively
(Middleton et al., 2002; Jarvis et al., 2007; Schmalhofer
et al., 2008; Xiao et al., 2010), on the evoked responses
of WDR neurons located in the deep dorsal horn of the
spinal cord. Our ﬁndings show that both drugs, via diﬀer-
ent routes of administration, signiﬁcantly inhibited neu-
ronal activity in the MIA group, suggesting a greater
contribution of Nav1.7 and 1.8 channel activity in mediat-
ing nociceptive transmission in the arthritic condition. This
Fig. 3. Neuronal responses evoked by brush, vF 26 and 60 g and 40 and 45 C heat were signiﬁcantly inhibited after systemic administration of
A-803467 in the MIA group only. Comparison of the eﬀects of systemic administration of A-803467 (3 and 30 mg/kg) on the evoked neuronal
responses to electrical (a,b), dynamic brush (c,d), mechanical punctate (e, f) and thermal stimulation (g,h) of the peripheral receptive ﬁeld in sham
(n= 7, left panel) and MIA (n= 7, right panel) rats. ⁄Denotes signiﬁcance at 30 mg/kg compared with baseline control data, p< 0.05, two-way RM
ANOVA with Bonferroni test for multiple paired comparisons. Values are mean ± SEM.
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Fig. 4. Intraplantar administration of A-80347 signiﬁcantly reduced the Ad-, C-ﬁber, post-discharge, Input, Wind-up, brush, vF 8–60 g and 45 and
48 C heat evoked neuronal responses in the MIA group. Comparison of the eﬀects of intraplantar administration of A-803467 (10 and 50 lg/50 ll)
on the evoked neuronal responses to electrical (a,b), dynamic brush (c,d), mechanical punctate (e, f) and thermal stimulation (g,h) of the peripheral
receptive ﬁeld in sham (n= 6, left panel) and MIA (n= 7, right panel) rats. §Denotes signiﬁcance at 10 lg, ⁄denotes signiﬁcance at 50 lg
compared with baseline control data, p< 0.05, one-way or two-way RM ANOVA with Bonferroni test for multiple paired comparisons. Values are
mean ± SEM.
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Nav1.7 and 1.8 in dorsal root ganglia (DRG) neurons dur-
ing OA (Strickland et al., 2008). Further, both drugs pro-
duced ‘‘selective’’ inhibition of neuronal responses in the
pathological condition. This is key, since it means that
both drugs would allow physiological transmission yet
attenuate abnormal pathophysiological transmission.
Importantly, the in vivo electrophysiological technique
we have used not only enables measurement of low
threshold innocuous evoked neuronal activity, but also
suprathreshold evoked neuronal responses. Many pain
studies evaluate around a nociceptive threshold,
whereas clinical pain is almost always more severe,
thus our in vivo electrophysiological recordings provide
a correlate for the high-intensity pain scores reported by
patients, and therefore adds to the ﬁndings from
behavioral approaches.
The Nav1.7 channel is expressed in sensory and
sympathetic neurons and olfactory epithelial cells (Black
et al., 1996, 2012; Cummins and Waxman, 1997).
Several lines of evidence have ﬁrmly placed this channel
in pain pathways, with compelling evidence from genetic
studies of rare human pain states (see Refs. Dib-Hajj
et al., 2013). Indeed a mutation in the encoding gene for
Nav1.7 (SCN9A) has been associated with a greater pain
score in OA patients (Reimann et al., 2010), but see
(Valdes et al., 2011). Therefore targeting and modulating
aberrant activity of Nav1.7 channel activity should prove
useful for pain associated with OA. Our in vivo electro-
physiological data support this hypothesis since ProTxII
signiﬁcantly reduced low- and high-intensity mechanical
evoked neuronal responses, and complements in vivo
electrophysiological data from knockout (KO) mice where
Nav1.7 channels deleted from all sensory neurons pro-
duced a reduction of mechanical evoked neuronal
responses (Minett et al., 2012). Taken together these
ﬁndings conﬁrm the requirement of Nav1.7 activity for
mechanical evoked neuronal responses. Interestingly,
ProTxII also produced marked and signiﬁcant inhibitions
of the noxious heat-evoked neuronal response in the
MIA group. This also aligns with data from mutant mice
studies. Mice with a conditional KO of Nav1.7 (from a sub-
set of sensory neurons that expresses Nav1.8) do not dis-
play signs of hypersensitivity to heat stimuli after
undergoing burn model injury or in the CFA model of
inﬂammatory pain (Shields et al., 2012b), and signiﬁcant
reductions in the electrophysiological responses of spinal
neurons to noxious heat were seen in mice lacking Nav1.7
in all sensory neurons (Minett et al., 2012), although in the
same study the behavioral response to noxious heat in
the Hargreaves and hotplates tests were only attenuated
in mice where Nav1.7 was deleted in all sensory and sym-
pathetic neurons. Since ProTxII does not discriminate
between neuronal subpopulations our data complement
the ﬁndings of Shields et al. (2012b) and Minett et al.
(2012) and verify a role for Nav1.7-mediating noxious
thermal hyperalgesia.
In contrast to its inhibitory eﬀects on the natural
evoked neuronal responses in the MIA group, ProTxII
did not aﬀect the neuronal responses induced by
electrical stimulation. This may be because the barrageof activity induced by the train of 16 electrical stimuli
maybe too great for the drug at this dose to overcome.
It is also possible that natural mechanical- and thermal
evoked neuronal responses are more sensitive to the
inhibitory eﬀects of the drug. However the most likely
explanation is that under these conditions the channel
blockers prevent the transduction and/or transmission
from sensory receptors without global eﬀects on
peripheral nerve excitability. However in the presence of
these drugs physiological evoked responses of spinal
sensory neurons are reduced.
Expression of Nav1.7 channels were originally
proposed to be restricted to the peripheral nervous
system, however a recent study has demonstrated
expression on pre-terminal sensory axons and terminals
of DRG neurons in the dorsal horn (Black et al., 2012)
and the marked inhibitory eﬀects of spinal application of
ProTxII seen in the present study would agree with a cen-
tral spinal location for these channels. It was not possible
to ascertain whether or not a similar MIA state-dependent
eﬀect of ProTxII would be seen via diﬀerent administrative
routes as it has been reported that the drug is unable to
permeate the blood nerve barrier (Schmalhofer et al.,
2008), hence precluding assessment of its eﬀects via sys-
temic or local routes of administration. Nonetheless, the
ﬁndings from the present study indicate an increased
sensitivity of Nav1.7 channels, at least in spinal nocicep-
tive pathways and possibly DRG, in the arthritic condition,
suggesting that Nav1.7 channels located on central term-
inals within the dorsal horn and/or DRG are functionally
important under pathological conditions.
There is a large body of evidence linking Nav1.8
channel activity with the initiation and maintenance of
chronic pain (Amir et al., 2006; Eijkelkamp et al., 2012),
crucially this includes evidence from human genetic data
where gain of function mutations in neuropathic patients
demonstrates a link between Nav1.8 and the human pain
experience (Faber et al., 2012). As increases in Nav1.8
expression have been reported under persistent inﬂam-
matory pain conditions (Tanaka et al., 1998; Amaya
et al., 2000; Coggeshall et al., 2004; Villarreal et al.,
2005; Strickland et al., 2008; Belkouch et al., 2014) but
see (Shields et al., 2012a), it would be reasonable to pro-
pose that reducing Nav1.8 function, alongside improve-
ment in the bioavailability and tolerability of small
molecule Nav1.8 blockers, hold promise for their anal-
gesic potential in treating chronic inﬂammatory states
such as OA pain (Scanio et al., 2010; Zhang et al.,
2010b). Indeed A-803467 has been shown to signiﬁcantly
attenuate hypersensitive behavior in a variety of animal
models of inﬂammatory pain (Jarvis et al., 2007) including
OA pain (Schuelert and McDougall, 2012). This latter
study demonstrated an inhibitory eﬀect following intra
articular injection of A-803467 on the mechanosensitivity
of joint aﬀerents and a reduction in joint pain behavior
and secondary allodynia, conﬁrming an important role
for Nav1.8 channels in OA pain, but they did not investi-
gate the eﬀects of the drug in sham controls. Our ﬁndings
show that, regardless of route of administration,
A-803467 produced a signiﬁcant and preferential inhibition
of neuronal activity in the MIA group only, suggestive of a
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referred pain. In comparison A-803467, via all three
routes of administration, produced minor inhibitions of
neuronal activity in the sham group. Therefore our ﬁnd-
ings add to the literature since not only do we show that
A-803467 produced a marked antinociceptive eﬀect of
the drug in the MIA group, but the diﬀerential eﬀect of
the drug in the two groups suggests an alteration in func-
tional activity of Nav1.8 channels at both peripheral (nerve
and/or DRG) and central spinal locations in the arthritic
condition. Furthermore our ﬁndings provide a neuronal
correlate for the reduction of secondary allodynia
observed by Schuelert and McDougall (2012) since
A-803467 reduced the evoked neuronal responses to
mechanical stimulation of the hind paw.
Interestingly, A-803467, via all three routes of
administration, signiﬁcantly inhibited the dynamic brush-
evoked response in the MIA group only. The expression
of Nav1.8 VGSC was ﬁrst thought to be restricted to small
diameter unmyelinated nociceptive neurons, however
recent immunohistochemical data suggest that Nav1.8 is
not exclusive to nociceptors, but is, in fact, expressed in
relatively high levels (about 40%) of A-ﬁbers and also
present on C-low-threshold mechanoreceptors (C-LTMs)
(Shields et al., 2012a). Indeed it has been shown that
mechanical hypersensitivity requires C-LTMS (Seal et al.,
2009). Therefore it is not unexpected that A-803467 was
able to reduce the brush-evoked neuronal response.
Additionally, alterations in the electrophysiological proper-
ties of Ab-ﬁber low-threshold mechanoreceptors have
been reported in a surgically induced model of OA (Wu
andHenry, 2010). Thismay reﬂect a change in sodium cur-
rents in these aﬀerents and could underlie the preferential
eﬀect of A-803467 on the brush-evoked neuronal
responses seen in MIA rats in the present study. Further,
a recent study also reported a functional up-regulation of
Nav1.8 channels in Ab ﬁbers in a model of chronic inﬂam-
mation (Belkouchet al., 2014), thus it is possible that a simi-
lar up-regulation also occurs in this model of knee OA
which may contribute to the MIA-dependent inhibitory
eﬀect of A-803467 on the brush-evoked neuronal
response. Alternatively, A-803467 shows a preferential
aﬃnity for inactivated channels (Jarvis et al., 2007), it is
possible that a greater proportion of Nav1.8 channels are
in this conformational state in the MIA rats, since the
inactivation state of VGSCs can be induced by repeated
neuronal ﬁring and/or under conditions of sustained mem-
brane depolarization which is probable for OA as an
increased incidence of spontaneous activity and enhanced
responsiveness of joint nociceptors and dorsal horn neu-
rons has been reported (Schuelert and McDougall, 2006,
2008, 2009; McDougall et al., 2009; Rahman et al., 2009;
Sagar et al., 2010; Kelly et al., 2012, 2015; Bullock et al.,
2014). Taken together, our ﬁndings highlight further the
potential of Nav1.8 as an analgesic target and suggest that
blocking these channels could be eﬀective against tactile
allodynia in arthritic pain.
Spinal and systemic administration of A-803467 did
not aﬀect the neuronal responses induced by electrical
stimulation, compared with the eﬀects seen on the
responses induced by natural stimuli in the MIA group.As already mentioned, this could be due to the barrage
of activity induced by the train of 16 electrical stimuli
being too great for the drug, at the doses given, to
overcome. Again, the most likely explanation is that
under these conditions the channel blockers prevent the
transduction and/or transmission from sensory receptors
without global eﬀects on nerve excitability. By contrast
local peripheral administration of A-803467 produced
the most profound reductions in neuronal activity in the
MIA group including signiﬁcant inhibition of the electrical
evoked responses suggesting that this local high dose
alters nerve excitability, again, this may be due to an
increased peripheral expression of Nav1.8 channels or
due to a greater proportion of these channels being in
the inactivated state in the arthritic animals.
Interestingly, the data also suggest that the Nav1.8
channels located at peripheral nerve ﬁber endings in
distal areas play an important role in regulating
nociceptive transmission in the arthritic condition. For a
signiﬁcant proportion of OA patients, it is likely that a
large peripheral drive initiates and maintains OA pain,
(Kirwan et al., 1994; Creamer et al., 1996; Ethgen et al.,
2004) therefore for those OA pain patients, local
administration or systemic administration of a peripherally
restricted version of a Nav1.8 blocker would be an appro-
priate treatment option, as well as the obvious potential
for reduced CNS side eﬀects.CONCLUSION
The therapeutic utility of sodium channel blockers are not
traditionally recommended for the treatment of OA pain,
but given the large peripheral drive that follows the
development of OA alongside the evidence for abnormal
ﬁring in peripheral and central neurons in the arthritic
condition, implicates a key role for VGSCs in mediating
OA pain. Our ﬁndings support this hypothesis since the
action of ProTxII and A-803467, to favor an inhibition of
neuronal responses evoked by both low-threshold and
suprathreshold stimuli in the MIA group suggests for a
greater contribution of these channels, at peripheral and
central locations, to the arthritic pain condition.
Furthermore our protocol models secondary
hyperalgesia; blocking Nav1.7 and 1.8 channel activity
reduced neuronal activity evoked from a referred site
(hind paw). This is key because the level of sensitization
at sites distal to the diseased joint has been directly
linked to the level of pain experienced by OA patients
(Arendt-Nielsen et al., 2010). Therefore assessment of
the eﬀect of drugs on both primary and secondary
hyperalgesiawill be important for the development of future
medicines.
The model of MIA used in the present study exhibits
features of neuropathy, therefore drugs designed to
block VGSCs may have greater therapeutic use in OA
patients with neuropathic traits who are refractory to
classical medications such as NSAIDs. Certainly a
better understanding of the role of Nav1.7 and 1.8 in
mediating osteoarthritic pain will aid the development of
future analgesics and the ﬁndings from the present
study suggest that modulating the activity of Nav1.7 and
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could prove worthwhile for the treatment of OA pain and
merits further clinical investigation.COMPETING INTERESTS
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